Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Artelo Biosciences Inc

ARTL ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: HOLD

Last Close

$0.79

▲ +4.15%

Market Cap $3.63M · Vol 24.10K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$3.63M

Micro Cap

Div Yield

N/A

EPS Growth

+73.80%

YoY

RSI (14)

30.42

Momentum

Beta

0.00

vs Market

52W High

$31.20

97.47% below

52W Low

$0.71

12.07% above

Volume

24.10K

Avg 20.91K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

98.17%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Artelo Biosciences Inc (ARTL) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ARTL pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+9.60%

-31.88%

-66.23%

-78.05%

YTD

-78.41%

-97.39%

-97.78%

-99.66%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-12,879,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-343.49% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	+73.80%
Outstanding Shares	4.60M

Technical Indicators

50-Day SMA	$1.06
200-Day SMA	$3.78
RSI (14)	30.42
Beta	0.00
52-Week High	$31.20
52-Week Low	$0.71

Volume Today	24.10K
Avg Daily Volume (30D)	20.91K
Relative Volume	1.15x
Volatility (10D)	53.28
Volatility (30D)	88.23
Free Float	98.17%

Analyst Consensus

HOLD

Current Price $0.79

Mean Target N/A

52W Low$0.71 52W High$31.20

Current

Target

$0.71 $31.20

Current Analyst target

· 1 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00793XCX9

ISINUS04301G7060

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 12, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of therapeutics that modulate lipid-signaling pathways. The Company is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.